SCHEMBL7945978

SCHEMBL7945978

CC(C)(C)CC(=O)N1C[C@H](O)C[C@H]1C(N)=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.42
PIK3CD O00329 3/20 0.38
PIK3CA P42336 2/20 0.38
PIK3CG P48736 1/20 0.38
DPP4 P27487 6/20 0.37
DPP8 Q6V1X1 6/20 0.37
DPP9 Q86TI2 6/20 0.37
RIPK1 Q13546 1/20 0.35
VHL P40337 1/20 0.34
ALDH1A1 P00352 1/20 0.33
CNR2 P34972 1/20 0.32
DPP7 Q9UHL4 1/20 0.32
FAP Q12884 1/20 0.32
CYP1A2 P05177 1/20 0.31
POLB P06746 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C19 P33261 1/20 0.31
CCR2 P41597 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22512115 1.00 ATM (0.42) ATMPIK3CDPIK3CAPIK3CGDPP4
SCHEMBL22796893 1.00 ATM (0.42) ATMPIK3CDPIK3CAPIK3CGDPP4
SCHEMBL22511873 1.00 ATM (0.42) ATMPIK3CDPIK3CAPIK3CGDPP4
SCHEMBL22511867 1.00 ATM (0.42) ATMPIK3CDPIK3CAPIK3CGDPP4
SCHEMBL24327073 0.89 PEPD (0.34) ATMPIK3CDPIK3CAPIK3CGDPP4
SCHEMBL883190 0.89 PEPD (0.34) ATMPIK3CDPIK3CAPIK3CGDPP4
SCHEMBL26251347 0.85 ATM (0.47) ATMPIK3CDDPP4DPP8DPP9
SCHEMBL22402907 0.85 ATM (0.61) ATMPIK3CDDPP4DPP8DPP9
SCHEMBL10215042 0.81 ATM (0.42) ATMPIK3CDPIK3CAPIK3CGDPP4
SCHEMBL24482547 0.81 VHL (0.52) ATMDPP4DPP8DPP9RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230241227-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR DBD THERAPEUTICS, LLC 2023-08-03 US disclosed
US-11547759-B2 Bi-functional compounds and methods for targeted ubiquitination of androgen receptor MONTELINO THERAPEUTICS, INC. (US) 2023-01-10 US disclosed
WO-2022111526-A1 BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF 四川海思科制药有限公司 2022-06-02 WO disclosed
WO-2022109396-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2022-05-27 WO disclosed
WO-2022109426-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2022-05-27 WO disclosed
WO-2022068933-A1 COMPOUNDS AND METHODS OF TREATING DISEASES CULLGEN (SHANGHAI) , INC. (CN) 2022-04-07 WO disclosed
WO-2021188696-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed
WO-2021162493-A1 PROTEIN KINASE DEGRADATION INDUCING COMPOUND, AND USE THEREOF 보로노이 주식회사 2021-08-19 WO disclosed
WO-2021155321-A2 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2020227325-A1 HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2020-11-12 WO disclosed
WO-2020200291-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI) , INC. (CN) 2020-10-08 WO disclosed
WO-2020206424-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-10-08 WO disclosed
US-20200282068-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR DBD THERAPEUTICS, LLC 2020-09-10 US disclosed
WO-2018013559-A1 NOVEL COMPOUNDS AND USES THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2018-01-18 WO disclosed
US-20170327469-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2017-11-16 US disclosed
WO-2010045266-A1 THERAPEUTIC ANTIVIRAL PEPTIDES INTERMUNE, INC. (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230241227-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR AR, ADRM1, PSMA3 ATM 3270/4885PIK3CD 2361/4885PIK3CA 2575/4885
US-20200282068-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR AR, ADRM1, PSMA3 ATM 3270/4885PIK3CD 2361/4885PIK3CA 2575/4885
US-20170327469-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, MDM2, ESRRA ATM 1477/4885PIK3CD 3535/4885PIK3CA 2602/4885
US-11547759-B2 Bi-functional compounds and methods for targeted ubiquitination of androgen receptor AR, ADRM1, PSMA3 ATM 3189/4885PIK3CD 2275/4885PIK3CA 2451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.